Frequency Therapeutics Provides Business Updates and Q3 2020 Financial Results
WOBURN, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the third quarter ended September 30, 2020. The company has continued to advance the clinical…
Read MoreFrequency Therapeutics Expands FX-322 Clinical Development Program; Announces Upcoming Day-90 Phase 2a Analysis
WOBURN, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today provided an update to its strategy and clinical development program for FX-322, its lead product candidate for the treatment of acquired sensorineural…
Read MoreFrequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss
WOBURN, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, has announced the completion of enrollment of its Phase 2a study of FX-322 for sensorineural hearing loss (SNHL). The company anticipates obtaining full…
Read MoreFrequency Therapeutics Finds Sustained Improvement in Hearing Loss Patients Treated with FX-322
WOBURN, MASSACHUSETTS – Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today presented clinical results from a longer-term durability study of FX-322, showing that some patients with chronic sensorineural hearing loss had significant improvement…
Read More
Frequency Therapeutics Provides Business Updates and Reports Q2 2020 Financial Results
WOBURN, MASSACHUSSETTS — Frequency Therapeutics, a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the second quarter ended June 30, 2020. “We are pleased with the steady progress in our Phase 2a…
Read More
Frequency Therapeutics Announces $42 Million Private Placement
WOBURN, MASSACHUSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, announced this week that it has agreed to sell 2,350,108 shares of its common stock in a private placement to institutional and accredited investors.…
Read MoreNew Frequency Therapeutics Study Confirms Drug Delivery to the Inner Ear
WOBURN, MASSACHUSETTS — Frequency Therapeutics, Inc., announced top-line data from an exploratory clinical study designed to show whether drug levels of FX-322 in the cochlea can be directly measured. In addition to confirming the viability of the approach, study results showed measurable concentrations of FX-322 in every patient and that anatomical factors did not prevent…
Read MoreFrequency Therapeutics Provides Business Updates and Reports Q3 2019 Financial Results
WOBURN, MASSACHUSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, has announced business updates and financial results for the third quarter ending September 30, 2019. “This has been a tremendously productive period for…
Read MoreFDA Grants FX-322 Fast Track Designation, for Treatment of Sensorineural Hearing Loss
WOBURN, MASSACHUSETTS — Biotech startup Frequency Therapeutics today announced that dosing has commenced in a Phase 2a clinical study of FX-322, a locally administered investigational drug candidate designed to regenerate auditory hair cells and restore hearing function. The objectives of the Phase 2a study are to further establish the positive hearing signal observed in Frequency’s…
Read More
Frequency Therapeutics Goes Public; Company Debuts IPO at $84M
WOBURN, MASSACHUSSETTS — Biotech startup Frequency Therapeutics announced the pricing of its initial public offering (IPO) at approximately $84 million. The company is planning to use funds raised by the IPO to complete the Phase 2a trial of FX-322, a regenerative therapeutic for the treatment of sensorineural hearing loss and also to advance discovery programs…
Read More